Drug Safety Evaluation in China

被引：0
作者：
Lisha Li
Jia Yin
机构：
[1] Peking Union Medical College Hospital,Department of Allergy, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment on Allergic Diseases, National Clinical Research Center for Immunologic Diseases
[2] Chinese Academy of Medical Sciences & Peking Union Medical College,undefined
来源：
Current Allergy and Asthma Reports | 2019年 / 19卷
关键词：
Drug safety evaluation; China; Good laboratory practice; Good clinical practice; Adverse drug reaction; Traditional Chinese medicine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 149 条
[1]  
Xu H(2016)Current situation and countermeasure of drug safety supervision and management in China Chin Med Mod Dist Educ Chin 14 29-31
[2]  
Lu Z(2015)Comprehensive evaluation of drug non-clinical safety evaluation Beijing Med J 37 208-209
[3]  
Lu G(2008)China’s good laboratory practice and mutual acceptance of safety data Chin Pharm Aff 22 531-533
[4]  
Li L(2005)Introduction of GLP in China Her Med 24 751-752
[5]  
Lv L(2007)Overview of good laboratory practice (GLP) China Pharm 10 36-39
[6]  
Chen J(2017)Research advances of new techniques and methods for drug safety evaluation Chin J Pharm 48 341-350
[7]  
Zhang Q(2013)The current situation, problems and the thoughts concerning the construction of the GLP quality systems in China Cap Med 24 17-19
[8]  
Pang J(2017)Accelerating GLP construction and MAD process in China Int Econ Coop 12 16-19
[9]  
Xiong Z(2017)Construction of quality management system with Chinese characteristic for drug clinical trial institution Chin J Clin Pharmacol 33 1039-1041
[10]  
Li B(2016)Discussion on standardization of adverse event management in drug clinical trials Heilongjiang Med J 40 1051-1052
12345678910